Evidence is accumulating of the clinical utility of single nucleotide polymorphisms to effectively stratify risk of breast cancer. Yet for this personalized polygenic information to be translated to clinical practice, consideration is needed about how this personalized risk information should be communicated and the impact on risk perception. This study examined the psychosocial implications and the impact on risk perception of communicating personalized polygenic breast cancer risk to high-risk women. High-risk women with a personal history of breast cancer and an uninformative BRCA1/2 result were genotyped in the Variants in Practice study for 22 breast cancer single nucleotide polymorphisms. Participants in the highest quartile of polygenic breast cancer risk were invited to receive their individual research results. Two personalized visual risk communication tools were used to facilitate communication of the polygenic information. Participants subsequently undertook a semi-structured interview examining their experience of receiving their polygenic breast cancer risk and their breast cancer risk perception. Thirty-nine women opted to receive their results and were interviewed. The women described the risk communication tools as helpful as the tool enabled comparison of their personalized breast cancer risk to the general population. Participants incorporated the polygenic risk information into their breast cancer risk perception, which for some reawakened feelings of being at risk years after an uninformative BRCA1/2 result. However, few reported any detrimental emotional impact. The delivery of personalized polygenic breast cancer risk to high-risk women informed and modified their breast cancer risk perception with little emotional impact.
Introduction
Research efforts to identify significant heritable factors to further explain the etiology of breast cancer have more recently focused on single nucleotide polymorphisms (SNPs) (Li et al. 2016; Mavaddat et al. 2015) . Genome-wide association studies have identified over 90 SNPs that collectively explain1 6% of familial breast cancer risk (Michailidou et al. 2015; Michailidou et al. 2013) . Studies combining polygenic risk with existing risk prediction models demonstrate improvements in breast cancer risk prediction tools that could be effective in the stratification of breast cancer risk for women with and without family history (Li et al. 2016; Mavaddat et al. 2015; Maxwell and Nathanson 2013; Sawyer et al. 2012; Vachon et al. 2015) . Despite this evidence, translation of combined SNP testing to clinical genetics practice has been slow, possibly due to a continued focus on single gene disorders and only recent evidence of SNP clinical utility (Shieh et al. 2016) .
Research examining hypothetical interest towards SNP testing consistently indicates that participants with and without personal and family histories of cancer possess positive attitudes towards being offered genomic testing for cancer risk (Graves et al. 2011; Hall et al. 2015; Henneman et al. 2011; Leventhal et al. 2013 ). More recently, cancer SNP testing has been offered to research participants to examine the psychosocial implications of genomic risk profiling and provide evidence for future translation of this testing from research to clinical settings (Bancroft et al. 2015; Nusbaum et al. 2013; Yanes et al. 2017; Young et al. 2017) . Participants in a prostate cancer screening study who all had a family history of prostate cancer could accurately recall their personalized risk result, did not experience distress, and were reassured by their risk profile information (Bancroft et al. 2014; Bancroft et al. 2015) . Similarly, all participants recruited to a pilot study in a primary care setting accepted SNP testing for colon cancer due to their curiosity, to improve the accuracy of their personal medical information, and because of the perceived implications of SNP results for future generations (Nusbaum et al. 2013 ). The participants from both these studies reported their personalized result did not influence their screening intentions, which is reassuring given the SNP testing offered by both these studies did not have any proof of clinical utility (Bancroft et al. 2014; Bancroft et al. 2015; Nusbaum et al. 2013) .
The translation of SNP testing from research to clinical settings requires consideration about how personalized risk should be communicated and how this information may impact patients' risk perception (Chowdhury et al. 2013; Sawyer et al. 2012 ). Austin and Honer (2008) describe a psychiatric genetic counseling model that incorporates a visual aid to facilitate understanding about the genetic contribution towards the development of psychiatric conditions. While participants were not specifically asked to give feedback about the visual aid, they all reported their understanding of the genetic and environmental causes of psychiatric illness had increased when followed up 1 month after the genetic counseling session (Austin and Honer 2008) . Furthermore, using personalized visual risk communication tools is preferred by the general community when considering the communication of polygenic cancer risk (Smit et al. 2016) , and when used are demonstrated to improve understanding of risk (Gigerenzer and Edwards 2003) . The use of visual aids or tools to assist with understanding and perception of risk is one of many approaches established in genetic counseling practice for cancer genetics, although risk tends to be verbally communicated (Julian-Reynier et al. 2003; Lobb et al. 2003) .
As evidence is accumulating of the clinical utility of breast cancer SNPs, translation of this information from research to the clinic is becoming more realistic (Li et al. 2016) . Nevertheless, there is a lack of critical examination of the psychosocial implications of communicating polygenic breast cancer risk information or empirical evidence of the use of personalized risk communication tools to facilitate this disclosure. This study invited research participants with a personal history of breast cancer and an uninformative BRCA1/2 result, to receive their polygenic breast cancer risk information. Disclosure of this personalized breast cancer risk information was facilitated using two visual risk communication tools.
This study aims to examine women's experiences of receiving polygenic breast cancer risk information and explores how this information impacted their breast cancer risk perception.
Methods

Study population
This study was approved by the Human Research Ethics Committee at the Peter MacCallum Cancer Centre, Victoria, Australia (ID 11.43, 11.08) . Participants were women enrolled in the Victorian Familial Breast and Ovarian Cancer Cohort (VFBOCC). This cohort comprises women at high risk of breast and ovarian cancer based on a personal and family history of cancer who did not have a BRCA1/2 mutation detected during clinical genetic testing and controls who were women selected from the Australian voting register (Sawyer et al. 2012) . The VFBOCC participants were genotyped for 22 breast cancer SNPs, from which a PRS was calculated with corresponding relative and absolute risks for breast cancer (Sawyer et al. 2012) . At the time of genotyping, moderaterisk genes (e.g., CHEK2, PALB2, ATM, and BRIP) were not included in the research protocol. The high-risk women were stratified into quartiles according to PRS, with significant clinical differences observed between the lowest and highest quartiles (Sawyer et al. 2012 ). These differences included earlier age of breast cancer diagnoses and an increase in the number of second primary breast cancers in women in the highest quartile (Sawyer et al. 2012) .
Sixty-eight participants with a PRS in the highest breast cancer risk quartile were identified as potential participants for this psychosocial study. Of these, three were excluded because they were not English speakers or had a psychiatric diagnosis. Of the 65 women who were sent invitation letters, 19 declined to participate, one was deceased, and six accepted then dropped out of the study. After consenting, participants were invited to receive their research results, i.e., SNP profile, in-person from the coauthors PJ or MAY, both of whom also conduct clinical genetics sessions, at the Familial Cancer Centre at the Peter MacCallum Cancer Centre, Australia. For the purposes of returning the results, there was no further stratification of participants, beyond having a PRS in the highest quartile. During the feedback session, participants' personalized breast cancer risk was disclosed in terms of relative and absolute risk, and contextualized in comparison to the general population to demonstrate their increased risk status. In addition to disclosing participants' polygenic risk, the inheritance of SNPs and risk to family members were also discussed during the feedback session. Participants' understanding of the inheritance of SNPs and risk to family members has been described in a companion paper .
Returning breast cancer risk results using visual risk communication tools
Two visual risk communication tools were annotated for each participant with their risk figures and used with every participant to assist the delivery of the breast cancer risk information (Sawyer et al. 2012) . The first tool consisted of a graph that presented the skewed normal distribution curve of breast cancer relative risks for familial breast cancer cases and controls (Fig. 1) . The graph included an indication of the average breast cancer risk for the Australian general population (RR = 1.0), the individual participants' personalized relative risk, and lifestyle risk factors: alcohol consumption (RR = 1.13) and body mass index above 30 (RR = 1.25) (Hamajima et al. 2002; Parkin and Boyd 2011) . The relative risk of breast cancer for BRCA1/2 mutation carriers (RR > 10) was greater than the range derived from SNP data (highest relative risk was 4.2) and was indicated separately on the bottom right side of the graph (Antoniou et al. 2003) . This risk communication tool was developed specifically by the coauthors SS and PJ to deliver the personalized risk information to the participants.
The second risk communication tool consisted of a pictograph, or icon array, with 100 women and was used to present absolute risk of breast cancer (Galesic et al. 2009 ). Participants' breast cancer risks were indicated by the number of women colored pink (Fig. 2 ).
Data collection
Participants undertook a qualitative semi-structured interview examining their experience of receiving their personalized research-based polygenic breast cancer risk result in a clinical setting, approximately 1 week after receiving their PRS. The semi-structured interviews were conducted by investigators SS and LF either in person or via telephone and were audiorecorded and then transcribed verbatim. Transcripts were deidentified, participants assigned pseudonyms, and the data were thematically analyzed. The analysis was informed by grounded theory; transcripts were analyzed iteratively taking an inductive approach using constant comparison to stimulate the emergence of ideas, categories, and concepts, which were then organized into themes (Glaser and Strauss 1967; Strauss and Corbin 1994) .
Results
Thirty-nine women received their PRS and participated in a follow-up interview. Fourteen were interviewed in-person, with the remainder conducted via telephone due to participants' geographic location. Interviews ranged from 19 to 88 min in length. Overarching key themes were identified that illustrate participants' understanding of SNPs and perception of their polygenic breast cancer risk. Findings describing participants' understanding of the inheritance of polygenic information and perceived utility of personalized genetic profiling have been published in a companion paper ). This paper presents findings from the interviews describing how the visual risk communication tools and receipt of the polygenic results influenced participants' risk perception. Specifically, how the use of two visual risk communication tools in the feedback session facilitated objective aspects of risk perception, and how receiving polygenic breast cancer risk information impacted participants' subjective risk perception. This paper presents two key themes: (1) the influence of visual risk communication tools on breast cancer risk perception and (2) forewarning or reawakening subjective risk perception.
Participant description
Participants were aged 38-83 years and all had a previous diagnosis of breast cancer with an average age of onset of 46.7 years (range 28-66 years) ( Table 1) . Participants were receiving their SNP results an average of 7.3 years after they attended the clinic to receive their BRCA1/2 genetic test results. Participants' PRS ranged from 0.62 to 2.10, and the range of corresponding breast cancer RR was 1.4-4.2. Six (15%) participants had no close family members with a breast cancer diagnosis and two participants each had one male family member with a breast cancer diagnosis ( Table 2) . As a result of their previous diagnosis, all participants had undergone breast cancer surgery but eight participants could not recall their breast cancer surgery type (Table 3) . Twelve participants had also undergone a bilateral salpingooophorectomy (BSO). Participants of this study had an average breast cancer relative risk of 1.96 (range 1.4-4.2).
Influence of visual risk communication tools on breast cancer risk perception
The two visual risk communication tools facilitated participants' perception of their risks by supporting them to translate their visually represented risk to a personalized numerical risk, compare themselves to the breast cancer risk of the general population, and contextualize their genetic risk with lifestyle factors that infer increased breast cancer risk.
Visualizing and comparing polygenic breast cancer risk Participants said they found the two risk communication tools Bhelpful^when they received their polygenic breast cancer risk results. The tools were described as enabling them to Bsee^where their risk was on the graph, and the number of women Bhighlighted^indicating their personal risk was described by participants as Bclear as anything^(Saffron, RR 2.3). However, it was the inclusion of two lifestyle breast cancer risk factors that was seen as providing participants with context and a point of comparison to their genetic risk. rs13387042, rs13281615, rs10941679, rs11249433, rs1011970, rs2380205, rs704010, rs614367, rs10509168, rs12662670, rs1975930, rs8170, rs865686. This result suggests that this patient is at high risk of breast cancer.
Common genomic variants tested:
Patient sample has been genotyped for 22 common genomic variants that have a clinical and statistical significance with breast cancer risk.
Polygenic risk score calculated through the sum of the log odds ratios for each common genomic variant tested within specimen. Score has been standardized to the same metric using population controls.
Polygenic risk score category ranges:
Research has found that women with a high polygenic risk score have a two-fold increase in the incidence of a second primary cancer when compared to women with a low polygenic risk score. 
Translating visual representation to numerical breast cancer risk
Participants were able to translate the visual representation of their breast cancer risk, referencing the 100 women figure, to an objective, numerical description of their personal risk and describe how this compares to the general population. As Sally (RR 1.8) explained, risk of breast cancer for the general population is Busually about ten in one hundred but I'm eighteen in one hundred.^In contrast, fewer participants were also able to compare and contrast their relative risk with the general 
28%
Life time absolute risk of breast cancer:
The highlighted female symbols represent patients absolute lifetime risk of breast cancer derived from the polygenic risk score. However, for some others, the numerical description of breast cancer risk was confusing or incomprehensible.
there's a little bit of confusion about the difference between me having … double the risk of the norm and that risk being 20%. …so those figures and I'm not great with figures … feel like they're contradictory. You know, 20%, how does 20% add up to double and even though I know, well if 10% is the normal risk then 20% is double. But double feels bigger than 20% somehow, if that makes sense? (Alexandra, RR 1.8)
Rose could describe her absolute risk referring to the figure: Bthat's my absolute risk, and so that's obviously a hundred women, there's 24 pink ones^but struggled to marry this risk with her PRS of 1.27 described below the graph: Forewarning or reawakening: modifying subjective perception of breast cancer risk
Receiving their polygenic result stimulated participants' recall of their uninformative BRCA1/2 result in two contrasting ways. For some, the receipt of their polygenic result was regarded as unsurprising because they recalled being forewarned when they received their uninformative BRCA1/ 2 result about the possibility of Bmedical science^identifying another genetic cause of their breast cancer in the future. Other participants experienced a reawakening of feelings of being at-risk again, feelings they had earlier dismissed after receiving an uninformative BRCA1/2 test result. Regardless of whether participants felt forewarned about their risk or experienced a reawakening of their risk perception, few reported experiencing any detrimental emotional impact by receiving their polygenic risk result.
Awareness of Bother^genetic factors causing breast cancer risk
Despite receiving an uninformative BRCA1/2 result in the past, many participants said they were aware that there may have been Bother^genetic factors causing their personal and family history of breast cancer.
At the time, I had my initial counseling, the doctor who spoke to me … said … that with the family history even though we didn't have BRCA1 and 2, she believed looking at my family history that there was probably a strong likelihood that sometime in the future they may find other genes or genetic mutations or mutations that acted together to increase my risk of breast cancer. (Pia, RR 1.5)
Many participants recalled how Bpleased^they were when they learnt that they did not have a BRCA1/2 mutation, but remembered being informed Bthat there could be other reasons which the medical science is unable to find at that moment( Andrea, RR 1.4). This caveat from genetic health professionals at the time of BRCA1/2 testing forewarned participants that progressive development in genetic technologies might find a reason for their personal and family history of breast cancer in the future.
When we'd finished and they'd said that we didn't have the BRCA gene, they did say and … it's something I've kept in my mind … that it's most probably something that they haven't found yet. If there was a group of people in a family that had things that seemed to be related, it was most probably something that hadn't been found yet. (Clementine, RR 1.9)
Reawakening of breast cancer risk perception
Other participants experienced a reawakening of the feeling of being at-risk after they received their polygenic result. These women described a period of time between receiving their BRCA1/2 result and their polygenic result, where they perceived their risk of breast cancer to have been reduced and often assumed they were Bno more likely than anyone else … to get another cancer^(Patricia, RR 1.4) or were Bjust likeô ther women in the general population (Julie, RR 1.5).
…once my sister got sick [breast cancer] … I knew something was wrong with the BRCA1 and 2, … in '97 it wasn't that I was lead to believe, but it seemed very clear cut: you either carry the gene or not. So my assumption was I was just like anyone else in the general population for that small period (Julie, RR 1.5)
For these women, receiving their polygenic result brought the realization that their breast cancer risk still existed. Mary described her changing perception by likening her breast cancer risk to school grades and changing from being an BA^grade student to a BC^grade student:
Before I was getting an A [after receiving her BRCA1/2 result] and now I'm getting a C [after receiving polygenic risk result] (Mary, RR 2.9)
Personal impact of polygenic breast cancer risk
For many participants, regardless of whether their risk perception was reawakened or not, the presentation of breast cancer risks based on common variant information did not appear to profoundly impact their emotional state. Some demonstrated acceptance saying Byou've just got to live with it^(Mia, RR 1.6) or Bit's just something you accept really^(Clementine, RR 1.9). Alexandra (RR 1.8) described herself as Bnaively optimistic^because her Brisk doesn't feel risky,^but acknowledged that she may not fully appreciate the possibility that she could develop a second primary breast cancer, hence her positive outlook and risk perception. Other participants compared their personalized risk to the general population and still concluded that it was not something to worry about. 
Discussion
This study presents the first opportunity to describe how the delivery and receipt of polygenic risk scores for breast cancer influenced women's risk perception. Each participant's polygenic breast cancer risk information was delivered using two personalized visual risk communication tools: one displaying relative risk derived from the participant's PRS and marked on a graph of the population distribution of risk ( Fig. 1) and the other employing a natural frequency format of a grid comprised of 100 women displaying absolute lifetime risk (Fig. 2 ) (Gigerenzer and Hoffrage 1995) . Some participants found the numerical risk information represented by one tool more accessible compared to the other, while there were only a few participants who appeared to integrate both forms of information into their risk perception. Nevertheless, the frequency grid format appeared to be more easily understood, a commonly demonstrated phenomena (Kurzenhauser and Dieckmann 2009) , because unlike conditional probabilities or relative frequencies, natural frequency refers to the same class of observations, enabling participants to compare their personal breast cancer risk to the general population's risk of breast cancer (e.g., 18% compared to 9%) (Gigerenzer and Edwards 2003) . In contrast, the PRS presented on the graph as a ranking of relative risks (e.g., 1.27) was more challenging for some to comprehend, where they were particularly unable to marry the numerical risks presented in the two tools.
Objective and subjective risk perception
Risk perception and the meanings individuals ascribe to risk information are a marriage between subjective experience and objective numerical probabilities (d'Agincourt-Canning 2005) . It is possible that the inclusion of the lifestyle risk factors, body mass index over 30 and alcohol consumption, drew on participants' subjective experiences providing a counterpoint to the more abstract idea of SNPs to inform their breast cancer risk perception. Indeed, other studies have demonstrated that perceived risk of cancer can be more influenced by subjective experiences such as family history of cancer than numerical risk factors (Kenen et al. 2003; McAllister 2003) . There are many factors that influence and contribute towards the development of risk perception, including personal and familial experiences, contextual aspects, and delivery of new information (d'Agincourt-Canning 2005). As experiences are accumulated throughout life and context changes, so does risk perception (McAllister 2003) . In this way, risk perception can be modified (Austin 2010) . All the participants in this study previously had breast cancer and had undergone genetic counseling and testing for a BRCA1/2 mutation. These experiences may have contributed to a period of time where they considered the possibility that they might have a BRCA1/ 2 mutation and considered the significant, implied cancer risk for themselves and their family members. While all participants' genetic test results were uninformative, Bembodiedl ived experiences such as these have been demonstrated to inform risk perception (Abel and Browner 1998) . For example, some participants juxtaposed their experience of receiving an uninformative BRCA1/2 test result with their personal and family cancer history to explain how they felt forewarned because Bother genes or genetic mutations^may be identified in the future and were, therefore, generally unsurprised by the existence of their polygenic breast cancer risk. Whereas, others described a reawakening of their breast cancer risk after receiving their polygenic result, demonstrating how their risk perception was modified from being similar to women in the general population to an increased level.
Implications for genetic counseling practice
Determining women's polygenic risk, particularly those who are clinically high-risk yet have received an uninformative BRCA1/2 test result, offers more detailed and personalized breast cancer risk stratification than is currently available. Delivering information about the inheritance of SNPs has been proven to be acceptable to women, who understood the personal rather than familial nature of the information, the mode of inheritance, and the inferred risk of breast cancer but not ovarian cancer ). However, in order for this SNP information to be useful, the polygenic risk must be communicated to women in a manner that facilitates understanding and informs risk perception. Indeed, participants reported that the use of the two visual risk communication tools in this study informed their risk perception by providing objective and personalized numerical information in context with more subjective lifestyle risk information. The findings suggest that if and when SNP testing is integrated into clinical genetics practice, visual communication tools may be useful aids for genetic health professionals to incorporate into their practice when delivering polygenic results. Further research is required to formally evaluate and compare visual communication tools.
Limitations
This study is limited by the sample comprised predominantly of Caucasian, metropolitan women who had previously received genetic counseling and testing at the Familial Cancer Centre at the Peter MacCallum Cancer Centre. The women who responded to recruitment may have been women who were more receptive to learning new genetic information and were therefore less likely to negatively experience the receipt of this information. There are likely to be women who actively or passively declined to participate for whom the polygenic information would have had a more detrimental impact on their emotional and psychological well-being. If polygenic testing is to be successfully integrated into clinical practice, then we need to ensure these women are appropriately supported to assimilate the polygenic results into their risk perception. Furthermore, this study only included women with a personal history of breast cancer. It is unknown how women from high-risk families who do not have a personal history of breast cancer will perceive their polygenic risk if it falls in the highest group. For these reasons, a mixed methods psychosocial study is now being conducted to compare acceptability of the delivery and receipt of polygenic information to women.
Conclusion
In this study, the use of two personalized visual risk communication tools to aid the delivery of polygenic breast cancer risk information informed and modified women's breast cancer risk perception. Women were able to incorporate this information into their perceived risk of breast cancer with little emotional impact. This study demonstrates the successful delivery of polygenic information to women with a personal and familial history of breast cancer, aided by two personalized visual risk communication tools. Further research is required to examine whether women who are not at high risk of breast cancer are receptive to receiving polygenic breast cancer risk information and examine the associated psychosocial repercussions.
